Page last updated: 2024-08-07 16:30:28
Delta-type opioid receptor
A delta-type opioid receptor that is encoded in the genome of mouse. [OMA:P32300, PRO:DNx]
Synonyms
D-OR-1;
DOR-1;
K56;
MSL-2
Research
Bioassay Publications (143)
| Timeframe | Studies on this Protein(%) | All Drugs % |
|---|
| pre-1990 | 12 (8.39) | 18.7374 |
| 1990's | 30 (20.98) | 18.2507 |
| 2000's | 64 (44.76) | 29.6817 |
| 2010's | 32 (22.38) | 24.3611 |
| 2020's | 5 (3.50) | 2.80 |
Compounds (163)
Drugs with Inhibition Measurements
| Drug | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Publication(s) |
|---|
| bremazocine | Mus musculus (house mouse) | IC50 | 0.0015 | 1 | 3 |
| 6-methoxytryptoline | Mus musculus (house mouse) | IC50 | 10.0000 | 1 | 1 |
| acetazolamide | Mus musculus (house mouse) | Ki | 0.1310 | 2 | 2 |
| aminoglutethimide | Mus musculus (house mouse) | IC50 | 0.2700 | 1 | 1 |
| verapamil | Mus musculus (house mouse) | Ki | 1.7500 | 1 | 2 |
| celecoxib | Mus musculus (house mouse) | Ki | 25.0105 | 2 | 2 |
| cgs 15943 | Mus musculus (house mouse) | Ki | 0.0004 | 1 | 1 |
| clonidine | Mus musculus (house mouse) | Ki | 0.0141 | 1 | 1 |
| racemethorphan | Mus musculus (house mouse) | IC50 | 2.0000 | 1 | 3 |
| dichlorphenamide | Mus musculus (house mouse) | Ki | 0.6190 | 2 | 2 |
| ethoxzolamide | Mus musculus (house mouse) | Ki | 0.0165 | 2 | 2 |
| fentanyl | Mus musculus (house mouse) | IC50 | 0.6342 | 2 | 2 |
| fentanyl | Mus musculus (house mouse) | Ki | 0.5690 | 2 | 2 |
| hydrochlorothiazide | Mus musculus (house mouse) | Ki | 0.3090 | 2 | 2 |
| lomerizine | Mus musculus (house mouse) | IC50 | 2.4300 | 1 | 1 |
| mafenide | Mus musculus (house mouse) | Ki | 12.5850 | 2 | 2 |
| meperidine | Mus musculus (house mouse) | IC50 | 20.2500 | 2 | 2 |
| methazolamide | Mus musculus (house mouse) | Ki | 0.0320 | 2 | 2 |
| moxonidine | Mus musculus (house mouse) | Ki | 0.0778 | 1 | 1 |
| rolipram | Mus musculus (house mouse) | IC50 | 1.5000 | 1 | 1 |
| saccharin | Mus musculus (house mouse) | Ki | 12.2495 | 2 | 2 |
| sulfanilamide | Mus musculus (house mouse) | Ki | 12.6200 | 2 | 2 |
| sulpiride | Mus musculus (house mouse) | Ki | 0.6200 | 2 | 2 |
| sulthiame | Mus musculus (house mouse) | Ki | 0.1915 | 2 | 2 |
| zm 336372 | Mus musculus (house mouse) | IC50 | 0.1800 | 1 | 1 |
| zonisamide | Mus musculus (house mouse) | Ki | 0.0455 | 2 | 2 |
| physostigmine | Mus musculus (house mouse) | IC50 | 1.1821 | 1 | 2 |
| 4-toluenesulfonamide | Mus musculus (house mouse) | Ki | 39.4100 | 2 | 2 |
| carzenide | Mus musculus (house mouse) | Ki | 0.1050 | 2 | 2 |
| galantamine | Mus musculus (house mouse) | IC50 | 8.3973 | 1 | 2 |
| ketobemidone | Mus musculus (house mouse) | IC50 | 7.0000 | 1 | 1 |
| thymoquinone | Mus musculus (house mouse) | IC50 | 14.7200 | 1 | 1 |
| benzolamide | Mus musculus (house mouse) | Ki | 0.0120 | 2 | 2 |
| spiradoline | Mus musculus (house mouse) | Ki | 9.4000 | 1 | 1 |
| f 7302 | Mus musculus (house mouse) | Ki | 0.1140 | 1 | 1 |
| ursolic acid | Mus musculus (house mouse) | IC50 | 3.6000 | 1 | 1 |
| 4-amino-6-chloro-1,3-benzenedisulfonamide | Mus musculus (house mouse) | Ki | 4.2375 | 2 | 2 |
| disulphane | Mus musculus (house mouse) | Ki | 0.1050 | 2 | 2 |
| rilmenidine | Mus musculus (house mouse) | Ki | 0.0831 | 1 | 1 |
| brinzolamide | Mus musculus (house mouse) | Ki | 22.5015 | 2 | 2 |
| 2,4-disulfamyl-5-trifluoromethylaniline | Mus musculus (house mouse) | Ki | 2.9315 | 2 | 2 |
| adrenoglomerulotropin | Mus musculus (house mouse) | IC50 | 10.0000 | 1 | 1 |
| sigmoidin a | Mus musculus (house mouse) | IC50 | 14.4000 | 1 | 1 |
| 3-tritylthio-l-alanine | Mus musculus (house mouse) | Ki | 0.0260 | 1 | 2 |
| rivastigmine | Mus musculus (house mouse) | IC50 | 54.0000 | 1 | 1 |
| 5-amino-1,3,4-thiadiazole-2-sulfonamide | Mus musculus (house mouse) | Ki | 4.3300 | 2 | 2 |
| nicotine | Mus musculus (house mouse) | Ki | 0.4400 | 1 | 1 |
| u 69593 | Mus musculus (house mouse) | Ki | 1.0000 | 2 | 2 |
| morphiceptin, n-me-phe(3)- | Mus musculus (house mouse) | IC50 | 0.2430 | 1 | 3 |
| bw 373u86 | Mus musculus (house mouse) | Ki | 0.0009 | 2 | 2 |
| valdecoxib | Mus musculus (house mouse) | Ki | 27.0215 | 2 | 2 |
| enkephalin-leu, arg(6)- | Mus musculus (house mouse) | Ki | 0.0091 | 1 | 1 |
| 2-chloro-n(6)cyclopentyladenosine | Mus musculus (house mouse) | Ki | 0.2370 | 1 | 1 |
| 4-(alpha-(4-allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl)-n,n-diethylbenzamide | Mus musculus (house mouse) | IC50 | 0.0842 | 5 | 8 |
| 4-(alpha-(4-allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl)-n,n-diethylbenzamide | Mus musculus (house mouse) | Ki | 0.0050 | 6 | 6 |
| salvinorin a | Mus musculus (house mouse) | Ki | 7.0000 | 4 | 4 |
| 3,5-bis(trifluoromethyl)benzyl n-acetyltryptophan | Mus musculus (house mouse) | IC50 | 0.0015 | 1 | 1 |
| 3,5-bis(trifluoromethyl)benzyl n-acetyltryptophan | Mus musculus (house mouse) | Ki | 0.0007 | 1 | 1 |
| besonprodil | Mus musculus (house mouse) | IC50 | 0.0040 | 1 | 1 |
| 4-(2-aminoethyl)benzenesulfonamide | Mus musculus (house mouse) | Ki | 10.5800 | 2 | 2 |
| varenicline | Mus musculus (house mouse) | Ki | 0.3900 | 1 | 1 |
| sb 203580 | Mus musculus (house mouse) | IC50 | 0.0200 | 1 | 1 |
| zm 241385 | Mus musculus (house mouse) | Ki | 0.0008 | 1 | 1 |
| sch 58261 | Mus musculus (house mouse) | Ki | 0.0006 | 1 | 1 |
| n-(3-chloro-7-indolyl)-1,4-benzenedisulphonamide | Mus musculus (house mouse) | Ki | 0.0230 | 2 | 2 |
| cp 101,606 | Mus musculus (house mouse) | IC50 | 0.0070 | 1 | 1 |
| enkephalin, methionine | Mus musculus (house mouse) | IC50 | 0.0130 | 1 | 3 |
| enkephalin, leucine | Mus musculus (house mouse) | IC50 | 0.0142 | 5 | 7 |
| enkephalin, leucine | Mus musculus (house mouse) | Ki | 0.0046 | 3 | 3 |
| etorphine | Mus musculus (house mouse) | Ki | 0.0029 | 2 | 2 |
| tyrosyl-1,2,3,4-tetrahydro-3-isoquinolinecarbonyl-phenylalanyl-phenylalanine | Mus musculus (house mouse) | IC50 | 0.0100 | 2 | 2 |
| tyrosyl-1,2,3,4-tetrahydro-3-isoquinolinecarbonyl-phenylalanyl-phenylalanine | Mus musculus (house mouse) | Ki | 0.0012 | 1 | 1 |
| n(6)-cyclopentyladenosine | Mus musculus (house mouse) | Ki | 0.0970 | 1 | 1 |
| 7-diethylaminocoumarin-3-carboxylic acid | Mus musculus (house mouse) | IC50 | 0.2500 | 1 | 1 |
| vesamicol | Mus musculus (house mouse) | Ki | 0.0020 | 1 | 1 |
| flunarizine | Mus musculus (house mouse) | IC50 | 1.6700 | 1 | 1 |
| hmr 3647 | Mus musculus (house mouse) | IC50 | 40.0000 | 1 | 1 |
| mitragynine | Mus musculus (house mouse) | IC50 | 4.0000 | 1 | 1 |
| mitragynine | Mus musculus (house mouse) | Ki | 1.0110 | 1 | 1 |
| deltorphin | Mus musculus (house mouse) | IC50 | 0.0495 | 1 | 2 |
| u-50488 | Mus musculus (house mouse) | Ki | 3.2500 | 4 | 4 |
| bp 897 | Mus musculus (house mouse) | Ki | 0.0050 | 1 | 1 |
| dynorphin (1-17) | Mus musculus (house mouse) | Ki | 0.0098 | 1 | 1 |
| dynorphin (1-11) | Mus musculus (house mouse) | IC50 | 0.0289 | 1 | 1 |
| dynorphin (1-11) | Mus musculus (house mouse) | Ki | 0.0082 | 1 | 1 |
| benzene-1-3-disulfonamide | Mus musculus (house mouse) | Ki | 0.0435 | 2 | 2 |
| 7-methoxy-2-(4-methoxyphenyl)-3,4-dihydro-2H-1-benzopyran-4-one | Mus musculus (house mouse) | IC50 | 1.8600 | 1 | 1 |
| mangostin | Mus musculus (house mouse) | IC50 | 0.5800 | 1 | 1 |
| codeine | Mus musculus (house mouse) | IC50 | 10.0000 | 1 | 3 |
| dorzolamide | Mus musculus (house mouse) | Ki | 25.0045 | 2 | 2 |
| nalorphine | Mus musculus (house mouse) | IC50 | 0.1095 | 2 | 2 |
| naloxone | Mus musculus (house mouse) | IC50 | 125.0322 | 2 | 4 |
| naloxone | Mus musculus (house mouse) | Ki | 0.0370 | 1 | 1 |
| oxymorphone | Mus musculus (house mouse) | Ki | 0.5164 | 5 | 5 |
| topiramate | Mus musculus (house mouse) | Ki | 0.1300 | 2 | 2 |
| morphine | Mus musculus (house mouse) | IC50 | 0.3645 | 6 | 10 |
| beta-funaltrexamine | Mus musculus (house mouse) | IC50 | 0.0820 | 1 | 1 |
| endomorphin 1 | Mus musculus (house mouse) | IC50 | 855.0130 | 2 | 2 |
| endomorphin 2 | Mus musculus (house mouse) | IC50 | 255.0241 | 2 | 2 |
| way-151932 | Mus musculus (house mouse) | IC50 | 0.0800 | 1 | 1 |
| notopterol | Mus musculus (house mouse) | Ki | 10.0000 | 1 | 1 |
| alpha-cyano-4-hydroxycinnamic acid | Mus musculus (house mouse) | IC50 | 10.7000 | 1 | 1 |
| fosbretabulin | Mus musculus (house mouse) | IC50 | 1.0050 | 2 | 2 |
| Isoliquiritigenin 4,4'-dimethyl ether | Mus musculus (house mouse) | IC50 | 351.7000 | 1 | 1 |
| naltrexone | Mus musculus (house mouse) | IC50 | 0.0051 | 3 | 6 |
| naltrexone | Mus musculus (house mouse) | Ki | 0.0466 | 8 | 9 |
| enkephalin, ala(2)-mephe(4)-gly(5)- | Mus musculus (house mouse) | IC50 | 1.2415 | 2 | 2 |
| norbinaltorphimine | Mus musculus (house mouse) | IC50 | 0.0104 | 1 | 1 |
| norbinaltorphimine | Mus musculus (house mouse) | Ki | 0.0210 | 4 | 4 |
| dermorphin | Mus musculus (house mouse) | IC50 | 0.0389 | 3 | 5 |
| dermorphin | Mus musculus (house mouse) | Ki | 1.0040 | 1 | 1 |
| 6 beta-hydroxynaltrexone | Mus musculus (house mouse) | IC50 | 0.0097 | 2 | 7 |
| biphalin | Mus musculus (house mouse) | IC50 | 0.0104 | 3 | 3 |
| tyrosyl alanyl-glycyl-phenylalaninamide | Mus musculus (house mouse) | IC50 | 0.1200 | 1 | 1 |
| oxymorphindole | Mus musculus (house mouse) | Ki | 0.0008 | 2 | 2 |
| naltrindole | Mus musculus (house mouse) | IC50 | 0.0007 | 1 | 1 |
| naltrindole | Mus musculus (house mouse) | Ki | 0.0005 | 5 | 6 |
| clocinnamox | Mus musculus (house mouse) | Ki | 0.0027 | 1 | 1 |
| ro 25-6981 | Mus musculus (house mouse) | IC50 | 0.0060 | 1 | 1 |
| enkephalin, leucine-2-alanine | Mus musculus (house mouse) | IC50 | 0.0915 | 3 | 5 |
| pd 174494 | Mus musculus (house mouse) | IC50 | 0.0040 | 1 | 1 |
| 17-cyclopropylmethyl-6,7-didehydro-4,5-epoxy-5'-guanidinyl-3,14-dihydroxyindolo(2',3'-6,7)morphinan | Mus musculus (house mouse) | Ki | 0.0240 | 3 | 3 |
| gm 109 | Mus musculus (house mouse) | IC50 | 0.0100 | 1 | 1 |
| bms201038 | Mus musculus (house mouse) | IC50 | 0.0008 | 1 | 1 |
| st 1535 | Mus musculus (house mouse) | Ki | 0.0066 | 1 | 1 |
| 6'-guanidinonaltrindole | Mus musculus (house mouse) | Ki | 0.0203 | 1 | 1 |
| tan 67 | Mus musculus (house mouse) | Ki | 0.0014 | 1 | 1 |
| dysidenin | Mus musculus (house mouse) | Ki | 9.0000 | 1 | 1 |
| deltorphin ii, ala(2)- | Mus musculus (house mouse) | IC50 | 0.0004 | 1 | 1 |
| deltorphin i, ala(2)- | Mus musculus (house mouse) | IC50 | 0.0003 | 3 | 7 |
| deltorphin i, ala(2)- | Mus musculus (house mouse) | Ki | 0.0008 | 1 | 1 |
| akuammicine | Mus musculus (house mouse) | IC50 | 12.4946 | 1 | 2 |
| way-208466 | Mus musculus (house mouse) | IC50 | 5.0000 | 1 | 1 |
| ufp-502 | Mus musculus (house mouse) | IC50 | 0.0001 | 1 | 1 |
| ufp-502 | Mus musculus (house mouse) | Ki | 0.0000 | 1 | 1 |
| 2-(2-fluoro-5-methylphenyl)-4,5-dihydro-1h-imidazole | Mus musculus (house mouse) | Ki | 0.0053 | 1 | 1 |
| 6-deoxy-6-fluoronaltrexone | Mus musculus (house mouse) | IC50 | 0.0079 | 1 | 1 |
| dynorphin (1-17) | Mus musculus (house mouse) | Ki | 0.0085 | 1 | 1 |
| dynorphin a (1-11)-amide | Mus musculus (house mouse) | Ki | 0.0071 | 5 | 5 |
| h-dmt-tic-gly-nh-bzl | Mus musculus (house mouse) | Ki | 0.0000 | 1 | 1 |
| salvinorin b | Mus musculus (house mouse) | Ki | 1.0000 | 1 | 1 |
| sazetidine-a | Mus musculus (house mouse) | Ki | 1.9000 | 1 | 1 |
| benzovesamicol | Mus musculus (house mouse) | Ki | 0.0001 | 1 | 1 |
| dynorphin (1-17) | Mus musculus (house mouse) | IC50 | 0.0397 | 1 | 1 |
| salvinorin b ethoxymethyl ether | Mus musculus (house mouse) | Ki | 1.0000 | 1 | 1 |
| dynorphins | Mus musculus (house mouse) | IC50 | 0.0077 | 2 | 2 |
| gsk 1363089 | Mus musculus (house mouse) | IC50 | 0.0049 | 1 | 1 |
| ici 174865 | Mus musculus (house mouse) | IC50 | 0.7030 | 1 | 1 |
| 7-hydroxymitragynine | Mus musculus (house mouse) | IC50 | 0.6910 | 1 | 1 |
| 7-hydroxymitragynine | Mus musculus (house mouse) | Ki | 0.0900 | 1 | 1 |
| mitragynine pseudoindoxyl | Mus musculus (house mouse) | IC50 | 0.0610 | 1 | 1 |
| mitragynine pseudoindoxyl | Mus musculus (house mouse) | Ki | 0.0030 | 1 | 1 |
| 7-spiroindanyloxymorphone | Mus musculus (house mouse) | Ki | 0.0178 | 3 | 3 |
| cj 15,208 | Mus musculus (house mouse) | Ki | 4.1500 | 2 | 2 |
| knt 127 | Mus musculus (house mouse) | Ki | 0.0002 | 2 | 2 |
| 4-hydroxy-1-(2-methylpropyl)-2-oxo-N-(2-sulfamoylphenyl)-3-quinolinecarboxamide | Mus musculus (house mouse) | IC50 | 40.0000 | 1 | 1 |
| rk 682 | Mus musculus (house mouse) | IC50 | 4.5000 | 1 | 1 |
| byl719 | Mus musculus (house mouse) | IC50 | 2.2000 | 1 | 1 |
Drugs with Activation Measurements
| Drug | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Publication(s) |
|---|
| 1-(3-chlorophenyl)biguanide | Mus musculus (house mouse) | EC50 | 34.4000 | 2 | 2 |
| pirinixic acid | Mus musculus (house mouse) | EC50 | 4.8000 | 1 | 1 |
| enkephalin, d-penicillamine (2,5)- | Mus musculus (house mouse) | EC50 | 0.0100 | 1 | 1 |
| sorafenib | Mus musculus (house mouse) | EC50 | 0.0030 | 1 | 2 |
| enkephalin, leucine | Mus musculus (house mouse) | EC50 | 0.0740 | 1 | 1 |
| naloxone | Mus musculus (house mouse) | Kd | 0.0002 | 1 | 1 |
| naltrexone | Mus musculus (house mouse) | EC50 | 0.0044 | 1 | 1 |
| enkephalin, ala(2)-mephe(4)-gly(5)- | Mus musculus (house mouse) | EC50 | 0.0319 | 3 | 5 |
| biphalin | Mus musculus (house mouse) | EC50 | 0.0215 | 4 | 5 |
| naltrindole | Mus musculus (house mouse) | Kd | 0.0006 | 1 | 1 |
| 17-cyclopropylmethyl-6,7-didehydro-4,5-epoxy-5'-guanidinyl-3,14-dihydroxyindolo(2',3'-6,7)morphinan | Mus musculus (house mouse) | Kd | 0.0155 | 1 | 2 |
| deltorphin ii, ala(2)- | Mus musculus (house mouse) | EC50 | 0.0018 | 1 | 2 |
| h-dmt-tic-gly-nh-bzl | Mus musculus (house mouse) | Kd | 0.0005 | 1 | 1 |
| nutlin-3a | Mus musculus (house mouse) | Kd | 0.5000 | 1 | 1 |
| nociceptin | Mus musculus (house mouse) | EC50 | 0.0631 | 1 | 1 |
Drugs with Other Measurements
Discovery of 5-substituted tetrahydronaphthalen-2yl-methyl with N-phenyl-N-(piperidin-4-yl)propionamide derivatives as potent opioid receptor ligands.Bioorganic & medicinal chemistry, , Sep-15, Volume: 23, Issue:18, 2015
Design and synthesis of novel bivalent ligands (MOR and DOR) by conjugation of enkephalin analogues with 4-anilidopiperidine derivatives.Bioorganic & medicinal chemistry letters, , Oct-15, Volume: 25, Issue:20, 2015
Effect of anchoring 4-anilidopiperidines to opioid peptides.Bioorganic & medicinal chemistry letters, , Jun-01, Volume: 23, Issue:11, 2013
Synthesis and Pharmacology of a Novel κ Opioid Receptor (KOR) Agonist with a 1,3,5-Trioxazatriquinane Skeleton.ACS medicinal chemistry letters, , Aug-14, Volume: 5, Issue:8, 2014
Synthesis of a novel universal opioid receptor agonist with the 1,3,5-trioxazatriquinane skeleton and its pharmacologies.Bioorganic & medicinal chemistry letters, , Oct-15, Volume: 24, Issue:20, 2014
(+/-)-4-[(N-allyl-cis-3-methyl-4-piperidinyl)phenylamino]-N,N-diethylbenzamide displays selective binding for the delta opioid receptor.Bioorganic & medicinal chemistry letters, , Oct-18, Volume: 9, Issue:20, 1999
Optically pure (-)-4-[(N-allyl-3-methyl-4-piperidinyl)phenyl-amino]-N,N-diethylbenzami de displays selective binding and full agonist activity for the delta opioid receptor.Bioorganic & medicinal chemistry letters, , Dec-06, Volume: 9, Issue:23, 1999
Synthesis and biological evaluation of novel delta (δ) opioid receptor ligands with diazatricyclodecane skeletons.European journal of medicinal chemistry, , Volume: 69, 2013
Tuned-Affinity Bivalent Ligands for the Characterization of Opioid Receptor Heteromers.ACS medicinal chemistry letters, , Aug-09, Volume: 3, Issue:8, 2012
Novel delta opioid receptor agonists exhibit differential stimulation of signaling pathways.Bioorganic & medicinal chemistry, , Sep-01, Volume: 17, Issue:17, 2009
Syntheses of 4,6'-epoxymorphinan derivatives and their pharmacologies.Bioorganic & medicinal chemistry, , Apr-15, Volume: 16, Issue:8, 2008
Synthesis of a novel 6,14-epoxymorphinan derivative and its pharmacology.Bioorganic & medicinal chemistry letters, , Dec-15, Volume: 18, Issue:24, 2008
(+/-)-4-[(N-allyl-cis-3-methyl-4-piperidinyl)phenylamino]-N,N-diethylbenzamide displays selective binding for the delta opioid receptor.Bioorganic & medicinal chemistry letters, , Oct-18, Volume: 9, Issue:20, 1999
Optically pure (-)-4-[(N-allyl-3-methyl-4-piperidinyl)phenyl-amino]-N,N-diethylbenzami de displays selective binding and full agonist activity for the delta opioid receptor.Bioorganic & medicinal chemistry letters, , Dec-06, Volume: 9, Issue:23, 1999
Probes for narcotic receptor mediated phenomena. 26. Synthesis and biological evaluation of diarylmethylpiperazines and diarylmethylpiperidines as novel, nonpeptidic delta opioid receptor ligands.Journal of medicinal chemistry, , Dec-30, Volume: 42, Issue:26, 1999
Discovery of a novel class of substituted pyrrolooctahydroisoquinolines as potent and selective delta opioid agonists, based on an extension of the message-address concept.Journal of medicinal chemistry, , Sep-26, Volume: 40, Issue:20, 1997
Probes for narcotic receptor mediated phenomena. 23. Synthesis, opioid receptor binding, and bioassay of the highly selective delta agonist (+)-4-[(alpha R)-alpha-((2S,5R)-4-Allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl]- N,N-diethylbenzamide (SNC 80)Journal of medicinal chemistry, , Feb-28, Volume: 40, Issue:5, 1997
Synthesis and biological evaluation of 2-alkyl-2-methoxymethyl-salvinorin ethers as selective κ-opioid receptor agonists.Bioorganic & medicinal chemistry letters, , Oct-15, Volume: 25, Issue:20, 2015
Modification of the furan ring of salvinorin A: identification of a selective partial agonist at the kappa opioid receptor.Bioorganic & medicinal chemistry, , Feb-01, Volume: 17, Issue:3, 2009
Standard protecting groups create potent and selective kappa opioids: salvinorin B alkoxymethyl ethers.Bioorganic & medicinal chemistry, , Feb-01, Volume: 16, Issue:3, 2008
Toward a structure-based model of salvinorin A recognition of the kappa-opioid receptor.Journal of medicinal chemistry, , Mar-27, Volume: 51, Issue:6, 2008
Modulating β-arrestin 2 recruitment at the δ- and μ-opioid receptors using peptidomimetic ligands.RSC medicinal chemistry, , Nov-17, Volume: 12, Issue:11, 2021
Isolation and Pharmacological Characterization of Six Opioidergic Journal of natural products, , 01-22, Volume: 84, Issue:1, 2021
Amide Bond Bioisosteres: Strategies, Synthesis, and Successes.Journal of medicinal chemistry, , 11-12, Volume: 63, Issue:21, 2020
Structure-activity relationships of dynorphin a analogues modified in the address sequence.Journal of medicinal chemistry, , May-22, Volume: 46, Issue:11, 2003
Conformationally restricted deltorphin analogues.Journal of medicinal chemistry, , Oct-16, Volume: 35, Issue:21, 1992
Replacement of the peptide-backbone amides connecting Tyr-Gly and Gly-Gly in leucine-enkephalin with ketomethylene groups: synthesis and biological activity.Journal of medicinal chemistry, , Volume: 27, Issue:2, 1984
Synthesis and pharmacological characterization in vitro of cyclic enkephalin analogues: effect of conformational constraints on opiate receptor selectivity.Journal of medicinal chemistry, , Volume: 25, Issue:12, 1982
Synthesis and biological evaluation of 2-alkyl-2-methoxymethyl-salvinorin ethers as selective κ-opioid receptor agonists.Bioorganic & medicinal chemistry letters, , Oct-15, Volume: 25, Issue:20, 2015
Synthesis and biological evaluation of C-12 triazole and oxadiazole analogs of salvinorin A.Bioorganic & medicinal chemistry letters, , Mar-01, Volume: 19, Issue:5, 2009
Solid phase synthesis and evaluation of Tyr-Tic-Phe-Phe(p-NHCOCH(2)Br) ([Phe(p-bromoacetamide)(4)]TIPP), a potent affinity label for delta opioid receptors.Journal of medicinal chemistry, , Aug-29, Volume: 45, Issue:18, 2002
Synthesis and evaluation of isothiocyanate-containing derivatives of the delta-opioid receptor antagonist Tyr-Tic-Phe-Phe (TIPP) as potential affinity labels for delta-opioid receptors.Journal of medicinal chemistry, , Dec-28, Volume: 43, Issue:26, 2000
Synthesis and Pharmacology of a Novel κ Opioid Receptor (KOR) Agonist with a 1,3,5-Trioxazatriquinane Skeleton.ACS medicinal chemistry letters, , Aug-14, Volume: 5, Issue:8, 2014
Modification of the furan ring of salvinorin A: identification of a selective partial agonist at the kappa opioid receptor.Bioorganic & medicinal chemistry, , Feb-01, Volume: 17, Issue:3, 2009
Design, synthesis, and structure-activity relationship of novel opioid kappa-agonists.Bioorganic & medicinal chemistry, , Oct-15, Volume: 16, Issue:20, 2008
Standard protecting groups create potent and selective kappa opioids: salvinorin B alkoxymethyl ethers.Bioorganic & medicinal chemistry, , Feb-01, Volume: 16, Issue:3, 2008
Selective reversible and irreversible ligands for the kappa opioid receptor.Journal of medicinal chemistry, , Jun-12, Volume: 35, Issue:12, 1992
The effects of C-terminal modifications on the opioid activity of [N-benzylTyr(1)]dynorphin A-(1-11) analogues.Journal of medicinal chemistry, , Nov-12, Volume: 52, Issue:21, 2009
Design and synthesis of highly potent and selective cyclic dynorphin A analogs. 2. New analogs.Journal of medicinal chemistry, , Mar-19, Volume: 36, Issue:6, 1993
Synthesis and characterization of potent and selective mu-opioid receptor antagonists, [Dmt(1), D-2-Nal(4)]endomorphin-1 (Antanal-1) and [Dmt(1), D-2-Nal(4)]endomorphin-2 (Antanal-2).Journal of medicinal chemistry, , Feb-08, Volume: 50, Issue:3, 2007
Structure-activity relationships of dynorphin a analogues modified in the address sequence.Journal of medicinal chemistry, , May-22, Volume: 46, Issue:11, 2003
Synthesis and biological evaluation of 14-alkoxymorphinans. 11. 3-Hydroxycyprodime and analogues: opioid antagonist profile in comparison to cyprodime.Journal of medicinal chemistry, , Aug-04, Volume: 38, Issue:16, 1995
Electrophilic opioid ligands. Oxygen tethered alpha-methylene-gamma-lactone, acrylate, isothiocyanate, and epoxide derivatives of 6 beta-naltrexol.Journal of medicinal chemistry, , Jun-26, Volume: 35, Issue:13, 1992
Synthesis and biological evaluation of [125I]- and [123I]-4-iododexetimide, a potent muscarinic cholinergic receptor antagonist.Journal of medicinal chemistry, , Volume: 32, Issue:5, 1989
Application of the message-address concept in the design of highly potent and selective non-peptide delta opioid receptor antagonists.Journal of medicinal chemistry, , Volume: 31, Issue:2, 1988
Tuned-Affinity Bivalent Ligands for the Characterization of Opioid Receptor Heteromers.ACS medicinal chemistry letters, , Aug-09, Volume: 3, Issue:8, 2012
Investigation of the selectivity of oxymorphone- and naltrexone-derived ligands via site-directed mutagenesis of opioid receptors: exploring the "address" recognition locus.Journal of medicinal chemistry, , Mar-15, Volume: 44, Issue:6, 2001
Design, synthesis, and structure-activity relationship of novel opioid kappa-agonists.Bioorganic & medicinal chemistry, , Oct-15, Volume: 16, Issue:20, 2008
Syntheses of 4,6'-epoxymorphinan derivatives and their pharmacologies.Bioorganic & medicinal chemistry, , Apr-15, Volume: 16, Issue:8, 2008
Synthesis of a novel 6,14-epoxymorphinan derivative and its pharmacology.Bioorganic & medicinal chemistry letters, , Dec-15, Volume: 18, Issue:24, 2008
Synthesis and biological activities of cyclic lanthionine enkephalin analogues: delta-opioid receptor selective ligands.Journal of medicinal chemistry, , Aug-15, Volume: 45, Issue:17, 2002
Synthesis and pharmacology of metabolically stable tert-butyl ethers of morphine and levorphanol.Journal of medicinal chemistry, , Volume: 25, Issue:10, 1982
Evidence of the preferential involvement of mu receptors in analgesia using enkephalins highly selective for peripheral mu or delta receptors.Journal of medicinal chemistry, , Volume: 24, Issue:10, 1981
Synthesis and biological activity of fluoroalkylamine derivatives of narcotic analgesics.Journal of medicinal chemistry, , Volume: 23, Issue:9, 1980
Effect of anchoring 4-anilidopiperidines to opioid peptides.Bioorganic & medicinal chemistry letters, , Jun-01, Volume: 23, Issue:11, 2013
Synthesis and evaluation of new endomorphin analogues modified at the Pro(2) residue.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 19, Issue:15, 2009
Synthesis and evaluation of new endomorphin analogues modified at the Pro(2) residue.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 19, Issue:15, 2009
Structure-activity relationship of the novel bivalent and C-terminal modified analogues of endomorphin-2.Bioorganic & medicinal chemistry letters, , Apr-01, Volume: 15, Issue:7, 2005
Optimization of N-aryl-6-methoxy-1,2,3,4-tetrahydroquinolines as tubulin polymerization inhibitors.Bioorganic & medicinal chemistry, , Sep-01, Volume: 23, Issue:17, 2015
Synthesis and activity of Combretastatin A-4 analogues: 1,2,3-thiadiazoles as potent antitumor agents.Bioorganic & medicinal chemistry letters, , Feb-15, Volume: 17, Issue:4, 2007
Design, syntheses, and pharmacological characterization of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3'-carboxamido)morphinan analogues as opioid receptor ligands.Bioorganic & medicinal chemistry, , Apr-15, Volume: 23, Issue:8, 2015
Structure activity relationship studies of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3'-carboxamido)morphinan (NAQ) analogues as potent opioid receptor ligands: preliminary results on the role of electronic characteristics for affinBioorganic & medicinal chemistry letters, , Sep-15, Volume: 23, Issue:18, 2013
Tuned-Affinity Bivalent Ligands for the Characterization of Opioid Receptor Heteromers.ACS medicinal chemistry letters, , Aug-09, Volume: 3, Issue:8, 2012
Synthesis of novel triplet drugs with 1,3,5-trioxazatriquinane skeletons and their pharmacologies. Part 2: Synthesis of novel triplet drugs with the epoxymethano structure (capped homotriplet).Bioorganic & medicinal chemistry letters, , Oct-15, Volume: 21, Issue:20, 2011
14 beta-O-cinnamoylnaltrexone and related dihydrocodeinones are mu opioid receptor partial agonists with predominant antagonist activity.Journal of medicinal chemistry, , Mar-26, Volume: 52, Issue:6, 2009
Identification of a new scaffold for opioid receptor antagonism based on the 2-amino-1,1-dimethyl-7-hydroxytetralin pharmacophore.Journal of medicinal chemistry, , Oct-07, Volume: 47, Issue:21, 2004
Investigation of the selectivity of oxymorphone- and naltrexone-derived ligands via site-directed mutagenesis of opioid receptors: exploring the "address" recognition locus.Journal of medicinal chemistry, , Mar-15, Volume: 44, Issue:6, 2001
N-Substituted 9beta-methyl-5-(3-hydroxyphenyl)morphans are opioid receptor pure antagonists.Journal of medicinal chemistry, , Oct-08, Volume: 41, Issue:21, 1998
Opioid antagonist activity of naltrexone-derived bivalent ligands: importance of a properly oriented molecular scaffold to guide "address" recognition at kappa opioid receptors.Journal of medicinal chemistry, , Apr-26, Volume: 39, Issue:9, 1996
Synthesis and opioid receptor affinity of a series of aralkyl ethers of 6 alpha- and 6 beta-naltrexol.Journal of medicinal chemistry, , Dec-09, Volume: 37, Issue:25, 1994
Probes for narcotic receptor mediated phenomena. 18. Epimeric 6 alpha- and 6 beta-iodo-3,14-dihydroxy-17-(cyclopropylmethyl)-4,5 alpha-epoxymorphinans as potential ligands for opioid receptor single photon emission computed tomography: synthesis, evaluatiJournal of medicinal chemistry, , Jul-24, Volume: 35, Issue:15, 1992
Electrophilic opioid ligands. Oxygen tethered alpha-methylene-gamma-lactone, acrylate, isothiocyanate, and epoxide derivatives of 6 beta-naltrexol.Journal of medicinal chemistry, , Jun-26, Volume: 35, Issue:13, 1992
An approach to the design of receptor-type-selective non-peptide antagonists of peptidergic receptors: delta opioid antagonists.Journal of medicinal chemistry, , Volume: 34, Issue:6, 1991
Design of peptidomimetic delta opioid receptor antagonists using the message-address concept.Journal of medicinal chemistry, , Volume: 33, Issue:6, 1990
Binaltorphimine-related bivalent ligands and their kappa opioid receptor antagonist selectivity.Journal of medicinal chemistry, , Volume: 31, Issue:4, 1988
Synthesis and Pharmacology of a Novel μ-δ Opioid Receptor Heteromer-Selective Agonist Based on the Carfentanyl Template.Journal of medicinal chemistry, , 11-25, Volume: 63, Issue:22, 2020
Chemical space screening around PheBioorganic & medicinal chemistry letters, , 07-15, Volume: 28, Issue:13, 2018
Novel cyclic biphalin analogue with improved antinociceptive properties.ACS medicinal chemistry letters, , Sep-11, Volume: 5, Issue:9, 2014
The biological activity and metabolic stability of peptidic bifunctional compounds that are opioid receptor agonists and neurokinin-1 receptor antagonists with a cystine moiety.Bioorganic & medicinal chemistry, , Oct-15, Volume: 17, Issue:20, 2009
Identification of a new scaffold for opioid receptor antagonism based on the 2-amino-1,1-dimethyl-7-hydroxytetralin pharmacophore.Journal of medicinal chemistry, , Oct-07, Volume: 47, Issue:21, 2004
Structure-activity relationships of dynorphin a analogues modified in the address sequence.Journal of medicinal chemistry, , May-22, Volume: 46, Issue:11, 2003
Transformation of a kappa-opioid receptor antagonist to a kappa-agonist by transfer of a guanidinium group from the 5'- to 6'-position of naltrindole.Journal of medicinal chemistry, , Jun-21, Volume: 44, Issue:13, 2001
[2',6'-Dimethyltyrosine]dynorphin A(1-11)-NH2 analogues lacking an N-terminal amino group: potent and selective kappa opioid antagonists.Journal of medicinal chemistry, , Sep-13, Volume: 44, Issue:19, 2001
Investigation of the selectivity of oxymorphone- and naltrexone-derived ligands via site-directed mutagenesis of opioid receptors: exploring the "address" recognition locus.Journal of medicinal chemistry, , Mar-15, Volume: 44, Issue:6, 2001
Potent and selective indolomorphinan antagonists of the kappa-opioid receptor.Journal of medicinal chemistry, , Jul-13, Volume: 43, Issue:14, 2000
Mutational evidence for a common kappa antagonist binding pocket in the wild-type kappa and mutant mu[K303E] opioid receptors.Journal of medicinal chemistry, , Dec-03, Volume: 41, Issue:25, 1998
Synthesis and kappa-opioid antagonist selectivity of a norbinaltorphimine congener. Identification of the address moiety required for kappa-antagonist activity.Journal of medicinal chemistry, , Aug-06, Volume: 36, Issue:16, 1993
Role of the spacer in conferring kappa opioid receptor selectivity to bivalent ligands related to norbinaltorphimine.Journal of medicinal chemistry, , Volume: 34, Issue:4, 1991
Analgesic Opioid Ligand Discovery Based on Nonmorphinan Scaffolds Derived from Natural Sources.Journal of medicinal chemistry, , 02-10, Volume: 65, Issue:3, 2022
[no title available]ACS medicinal chemistry letters, , Nov-09, Volume: 8, Issue:11, 2017
Dermorphin and deltorphin heptapeptide analogues: replacement of Phe residue by Dmp greatly improves opioid receptor affinity and selectivity.Bioorganic & medicinal chemistry letters, , Mar-25, Volume: 12, Issue:6, 2002
Dermorphin and deltorphin glycosylated analogues: synthesis and antinociceptive activity after systemic administration.Journal of medicinal chemistry, , Feb-11, Volume: 42, Issue:3, 1999
Synthesis and opioid receptor affinity of a series of aralkyl ethers of 6 alpha- and 6 beta-naltrexol.Journal of medicinal chemistry, , Dec-09, Volume: 37, Issue:25, 1994
Electrophilic opioid ligands. Oxygen tethered alpha-methylene-gamma-lactone, acrylate, isothiocyanate, and epoxide derivatives of 6 beta-naltrexol.Journal of medicinal chemistry, , Jun-26, Volume: 35, Issue:13, 1992
Novel cyclic biphalin analogue with improved antinociceptive properties.ACS medicinal chemistry letters, , Sep-11, Volume: 5, Issue:9, 2014
Effect of anchoring 4-anilidopiperidines to opioid peptides.Bioorganic & medicinal chemistry letters, , Jun-01, Volume: 23, Issue:11, 2013
Biological and conformational evaluation of bifunctional compounds for opioid receptor agonists and neurokinin 1 receptor antagonists possessing two penicillamines.Journal of medicinal chemistry, , Aug-12, Volume: 53, Issue:15, 2010
A structure-activity relationship study and combinatorial synthetic approach of C-terminal modified bifunctional peptides that are delta/mu opioid receptor agonists and neurokinin 1 receptor antagonists.Journal of medicinal chemistry, , Mar-13, Volume: 51, Issue:5, 2008
Partial retro-inverso, retro, and inverso modifications of hydrazide linked bifunctional peptides for opioid and cholecystokinin (CCK) receptors.Journal of medicinal chemistry, , Jan-11, Volume: 50, Issue:1, 2007
Synthesis and biological activity of the first cyclic biphalin analogues.Bioorganic & medicinal chemistry letters, , Jan-15, Volume: 16, Issue:2, 2006
Effect of N-alkyl and N-alkenyl substituents in noroxymorphindole, 17-substituted-6,7-dehydro-4,5alpha-epoxy-3,14-dihydroxy-6,7:2',3'-indolomorphinans, on opioid receptor affinity, selectivity, and efficacy.Journal of medicinal chemistry, , Apr-26, Volume: 44, Issue:9, 2001
Discovery of a novel class of substituted pyrrolooctahydroisoquinolines as potent and selective delta opioid agonists, based on an extension of the message-address concept.Journal of medicinal chemistry, , Sep-26, Volume: 40, Issue:20, 1997
Design of peptidomimetic delta opioid receptor antagonists using the message-address concept.Journal of medicinal chemistry, , Volume: 33, Issue:6, 1990
Mitragynine/Corynantheidine Pseudoindoxyls As Opioid Analgesics with Mu Agonism and Delta Antagonism, Which Do Not Recruit β-Arrestin-2.Journal of medicinal chemistry, , 09-22, Volume: 59, Issue:18, 2016
Synthesis of quinolinomorphinan derivatives as highly selective δ opioid receptor ligands.Bioorganic & medicinal chemistry, , Oct-01, Volume: 20, Issue:19, 2012
Potent Dmt-Tic pharmacophoric delta- and mu-opioid receptor antagonists.Journal of medicinal chemistry, , Dec-15, Volume: 48, Issue:25, 2005
Identification of a new scaffold for opioid receptor antagonism based on the 2-amino-1,1-dimethyl-7-hydroxytetralin pharmacophore.Journal of medicinal chemistry, , Oct-07, Volume: 47, Issue:21, 2004
Discovery of the first N-substituted 4beta-methyl-5-(3-hydroxyphenyl)morphan to possess highly potent and selective opioid delta receptor antagonist activity.Journal of medicinal chemistry, , Jan-15, Volume: 47, Issue:2, 2004
Synthesis, opioid receptor binding, and functional activity of 5'-substituted 17-cyclopropylmethylpyrido[2',3':6,7]morphinans.Bioorganic & medicinal chemistry letters, , Feb-10, Volume: 13, Issue:3, 2003
Investigation of the selectivity of oxymorphone- and naltrexone-derived ligands via site-directed mutagenesis of opioid receptors: exploring the "address" recognition locus.Journal of medicinal chemistry, , Mar-15, Volume: 44, Issue:6, 2001
Synthesis, opioid receptor binding, and biological activities of naltrexone-derived pyrido- and pyrimidomorphinans.Journal of medicinal chemistry, , Sep-09, Volume: 42, Issue:18, 1999
Mutational evidence for a common kappa antagonist binding pocket in the wild-type kappa and mutant mu[K303E] opioid receptors.Journal of medicinal chemistry, , Dec-03, Volume: 41, Issue:25, 1998
Synthesis, opioid receptor binding, and bioassay of naltrindole analogues substituted in the indolic benzene moiety.Journal of medicinal chemistry, , Jul-16, Volume: 41, Issue:15, 1998
Discovery of a novel class of substituted pyrrolooctahydroisoquinolines as potent and selective delta opioid agonists, based on an extension of the message-address concept.Journal of medicinal chemistry, , Sep-26, Volume: 40, Issue:20, 1997
7'-Substituted amino acid conjugates of naltrindole. Hydrophilic groups as determinants of selective antagonism of delta 1 opioid receptor-mediated antinociception in mice.Journal of medicinal chemistry, , Feb-03, Volume: 38, Issue:3, 1995
Novel deltorphin heptapeptide analogs with potent delta agonist, delta antagonist, or mixed mu antagonist/delta agonist properties.Journal of medicinal chemistry, , Sep-29, Volume: 38, Issue:20, 1995
Synthesis of naltrexone-derived delta-opioid antagonists. Role of conformation of the delta address moiety.Journal of medicinal chemistry, , Mar-04, Volume: 37, Issue:5, 1994
An approach to the design of receptor-type-selective non-peptide antagonists of peptidergic receptors: delta opioid antagonists.Journal of medicinal chemistry, , Volume: 34, Issue:6, 1991
Design of peptidomimetic delta opioid receptor antagonists using the message-address concept.Journal of medicinal chemistry, , Volume: 33, Issue:6, 1990
Application of the message-address concept in the design of highly potent and selective non-peptide delta opioid receptor antagonists.Journal of medicinal chemistry, , Volume: 31, Issue:2, 1988
Probes for narcotic receptor-mediated phenomena. 20. Alteration of opioid receptor subtype selectivity of the 5-(3-hydroxyphenyl)morphans by application of the message-address concept: preparation of delta-opioid receptor ligands.Journal of medicinal chemistry, , Apr-28, Volume: 38, Issue:9, 1995
Replacement of the peptide-backbone amides connecting Tyr-Gly and Gly-Gly in leucine-enkephalin with ketomethylene groups: synthesis and biological activity.Journal of medicinal chemistry, , Volume: 27, Issue:2, 1984
Evidence of the preferential involvement of mu receptors in analgesia using enkephalins highly selective for peripheral mu or delta receptors.Journal of medicinal chemistry, , Volume: 24, Issue:10, 1981
Identification of (3R)-7-hydroxy-N-((1S)-1-[[(3R,4R)-4-(3-hydroxyphenyl)- 3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl)-1,2,3,4-tetrahydro- 3-isoquinolinecarboxamide as a novel potent and selective opioid kappa receptor antagonist.Journal of medicinal chemistry, , Jul-03, Volume: 46, Issue:14, 2003
Transformation of a kappa-opioid receptor antagonist to a kappa-agonist by transfer of a guanidinium group from the 5'- to 6'-position of naltrindole.Journal of medicinal chemistry, , Jun-21, Volume: 44, Issue:13, 2001
Investigation of the selectivity of oxymorphone- and naltrexone-derived ligands via site-directed mutagenesis of opioid receptors: exploring the "address" recognition locus.Journal of medicinal chemistry, , Mar-15, Volume: 44, Issue:6, 2001
Mutational evidence for a common kappa antagonist binding pocket in the wild-type kappa and mutant mu[K303E] opioid receptors.Journal of medicinal chemistry, , Dec-03, Volume: 41, Issue:25, 1998
Synthesis and Pharmacology of a Novel μ-δ Opioid Receptor Heteromer-Selective Agonist Based on the Carfentanyl Template.Journal of medicinal chemistry, , 11-25, Volume: 63, Issue:22, 2020
Effect of anchoring 4-anilidopiperidines to opioid peptides.Bioorganic & medicinal chemistry letters, , Jun-01, Volume: 23, Issue:11, 2013
Dermorphin and deltorphin heptapeptide analogues: replacement of Phe residue by Dmp greatly improves opioid receptor affinity and selectivity.Bioorganic & medicinal chemistry letters, , Mar-25, Volume: 12, Issue:6, 2002
Dermorphin and deltorphin glycosylated analogues: synthesis and antinociceptive activity after systemic administration.Journal of medicinal chemistry, , Feb-11, Volume: 42, Issue:3, 1999
Cyclic enkephalin analogs with exceptional potency at peripheral delta opioid receptors.Journal of medicinal chemistry, , Jan-07, Volume: 37, Issue:1, 1994
Conformationally restricted deltorphin analogues.Journal of medicinal chemistry, , Oct-16, Volume: 35, Issue:21, 1992
Role of 2',6'-dimethyl-l-tyrosine (Dmt) in some opioid lead compounds.Bioorganic & medicinal chemistry, , Aug-15, Volume: 18, Issue:16, 2010
Further studies on lead compounds containing the opioid pharmacophore Dmt-Tic.Journal of medicinal chemistry, , Aug-28, Volume: 51, Issue:16, 2008
The effects of C-terminal modifications on the opioid activity of [N-benzylTyr(1)]dynorphin A-(1-11) analogues.Journal of medicinal chemistry, , Nov-12, Volume: 52, Issue:21, 2009
Design, synthesis, and pharmacological activities of dynorphin A analogues cyclized by ring-closing metathesis.Journal of medicinal chemistry, , Sep-24, Volume: 52, Issue:18, 2009
Synthesis and opioid activity of side-chain-to-side-chain cyclic dynorphin A-(1-11) amide analogues cyclized between positions 2 and 5. 1. Substitutions in position 3.Journal of medicinal chemistry, , Jan-15, Volume: 47, Issue:2, 2004
Structure-activity relationships of dynorphin a analogues modified in the address sequence.Journal of medicinal chemistry, , May-22, Volume: 46, Issue:11, 2003
[2',6'-Dimethyltyrosine]dynorphin A(1-11)-NH2 analogues lacking an N-terminal amino group: potent and selective kappa opioid antagonists.Journal of medicinal chemistry, , Sep-13, Volume: 44, Issue:19, 2001
Conformationally constrained opioid ligands: the Dmt-Aba and Dmt-Aia versus Dmt-Tic scaffold.Bioorganic & medicinal chemistry letters, , Jan-15, Volume: 19, Issue:2, 2009
Further studies on lead compounds containing the opioid pharmacophore Dmt-Tic.Journal of medicinal chemistry, , Aug-28, Volume: 51, Issue:16, 2008
Effect of anchoring 4-anilidopiperidines to opioid peptides.Bioorganic & medicinal chemistry letters, , Jun-01, Volume: 23, Issue:11, 2013
Design and synthesis of highly potent and selective cyclic dynorphin A analogs. 2. New analogs.Journal of medicinal chemistry, , Mar-19, Volume: 36, Issue:6, 1993
Synthesis and evaluation of N,N-dialkyl enkephalin-based affinity labels for delta opioid receptors.Journal of medicinal chemistry, , Oct-19, Volume: 43, Issue:21, 2000
An approach to the design of receptor-type-selective non-peptide antagonists of peptidergic receptors: delta opioid antagonists.Journal of medicinal chemistry, , Volume: 34, Issue:6, 1991
Design of peptidomimetic delta opioid receptor antagonists using the message-address concept.Journal of medicinal chemistry, , Volume: 33, Issue:6, 1990
Investigation of the selectivity of oxymorphone- and naltrexone-derived ligands via site-directed mutagenesis of opioid receptors: exploring the "address" recognition locus.Journal of medicinal chemistry, , Mar-15, Volume: 44, Issue:6, 2001
7-spirobenzocyclohexyl derivatives of naltrexone, oxymorphone, and hydromorphone as selective opioid receptor ligands.Journal of medicinal chemistry, , Sep-12, Volume: 40, Issue:19, 1997
Analgesic Opioid Ligand Discovery Based on Nonmorphinan Scaffolds Derived from Natural Sources.Journal of medicinal chemistry, , 02-10, Volume: 65, Issue:3, 2022
Development of κ opioid receptor antagonists.Journal of medicinal chemistry, , Mar-28, Volume: 56, Issue:6, 2013
Synthesis of quinolinomorphinan derivatives as highly selective δ opioid receptor ligands.Bioorganic & medicinal chemistry, , Oct-01, Volume: 20, Issue:19, 2012
Design and synthesis of KNT-127, a δ-opioid receptor agonist effective by systemic administration.Bioorganic & medicinal chemistry letters, , Nov-01, Volume: 20, Issue:21, 2010